Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared on X:
“Now Out:
MARIPOSA Study: Amivantamab plus Lazertinib vs. Osimertinib in 1L EGFRm Advanced NSCLC – Final OS Results
Presented by Prof. James Yang
- OS HR: 0.75 (95% CI: 0.61–0.92)
- Expected to extend median OS (mOS) by at least 12 months
- NCT Number: NCT04487080″